On January 9th, CEC Capital ranked first on the "Medical and Health Sector Financial Advisor List" in the "2022 China Equity Investment Annual List" published by Qi Mingpian

As a leading financial data service platform in China, this ranking relied on Qimingpian's big data capabilities. Through rigorous research methods, including data capturing, questionnaire surveys, and data verification, institutions were comprehensively assessed to determine the final rankings.

CEC Capital is a leading investment bank in China’s new economy, focusing on the global healthcare, technology, and consumer industries. Healthcare is a key area of focus and strength for CEC Capital, which has ranked first in the number and amount of large private equity financing and M&A transactions in the Chinese medical and health industry for six consecutive years.

CEC Capital boasts the largest and most professional healthcare investment banking team in China, covering five major sub-sectors, including pharmaceuticals and biotechnology, medical and health services, medical technology and equipment, digital and AI, and M&A. 

In 2022, CEC Capital completed several major transactions in China's healthcare primary market, including significant financing deals for companies such as WuXi AppTec, HuiSheng Biotechnology, Yimei Cell, Berry Genomics, Viva Biotech, DeKang Medical, and Olink, as well as facilitating the strategic cooperation agreement between global in-vitro diagnostics learder bioMérieux and AccuNuome, among other notable deals.